Darrell Nix

1.2k total citations
21 papers, 876 citations indexed

About

Darrell Nix is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Darrell Nix has authored 21 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Oncology and 5 papers in Hematology. Recurrent topics in Darrell Nix's work include Protein Degradation and Inhibitors (5 papers), Peptidase Inhibition and Analysis (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Darrell Nix is often cited by papers focused on Protein Degradation and Inhibitors (5 papers), Peptidase Inhibition and Analysis (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Darrell Nix collaborates with scholars based in United States, Austria and Australia. Darrell Nix's co-authors include Dixie Esseltine, J J Schentag, P. Dieringer, Julian Adams, Christopher J. Logothetis, Randall E. Millikan, Timothy Madden, Hong Yang, Christine Pien and Danai Daliani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Darrell Nix

19 papers receiving 844 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Darrell Nix United States	9	566	378	329	78	72	21	876
Tamer E. Fandy United States	18	874 1.5×	318 0.8×	213 0.6×	40 0.5×	103 1.4×	37	1.2k
Yuichi Nakamura Japan	18	393 0.7×	242 0.6×	149 0.5×	43 0.6×	75 1.0×	62	1.0k
Abhisek Swaika United States	15	475 0.8×	267 0.7×	549 1.7×	35 0.4×	145 2.0×	30	1.1k
Mark Hong Lee South Korea	13	383 0.7×	197 0.5×	245 0.7×	37 0.5×	176 2.4×	63	904
Chaoxin Hu United States	13	434 0.8×	98 0.3×	367 1.1×	64 0.8×	128 1.8×	18	920
P. Thavasu United Kingdom	8	279 0.5×	151 0.4×	155 0.5×	36 0.5×	58 0.8×	10	644
Songfu Jiang China	18	361 0.6×	251 0.7×	418 1.3×	20 0.3×	86 1.2×	61	861
Jason M. Foulks United States	14	428 0.8×	282 0.7×	114 0.3×	20 0.3×	152 2.1×	31	850
Danian Nie China	18	297 0.5×	363 1.0×	147 0.4×	39 0.5×	64 0.9×	59	772
Lori Capone Switzerland	9	466 0.8×	307 0.8×	179 0.5×	90 1.2×	14 0.2×	13	1.0k

Countries citing papers authored by Darrell Nix

Since Specialization

Citations

This map shows the geographic impact of Darrell Nix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darrell Nix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darrell Nix more than expected).

Fields of papers citing papers by Darrell Nix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darrell Nix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darrell Nix. The network helps show where Darrell Nix may publish in the future.

Co-authorship network of co-authors of Darrell Nix

This figure shows the co-authorship network connecting the top 25 collaborators of Darrell Nix. A scholar is included among the top collaborators of Darrell Nix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darrell Nix. Darrell Nix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Babu, Suma, Katharine Nicholson, Jeffrey D. Rothstein, et al.. (2024). Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial. Brain. 147(9). 2998–3008. 11 indexed citations

Viader, Andreu, John Throup, Heike J. Wobst, et al.. (2024). JNT-517, a first-in-class SLC6A19 inhibitor for the treatment of phenylketonuria, enhances urinary excretion of phenylalanine in healthy volunteers. Molecular Genetics and Metabolism. 141(4). 108267–108267.

Lewinski, Dirk von, Joseph B. Selvanayagam, Richard A. Schatz, et al.. (2020). “Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction”: study protocol for a randomized controlled trial. Trials. 21(1). 744–744. 2 indexed citations

Rioux, Nathalie, Sherri Smith, Amy Kim, et al.. (2020). Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans. Xenobiotica. 50(9). 1101–1114. 3 indexed citations

Buchtele, Nina, Michael Schwameis, Christian Schoergenhofer, et al.. (2020). Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose‐escalating trial. British Journal of Clinical Pharmacology. 86(5). 979–990. 7 indexed citations

Diefenbach, Catherine, Jonathan B. Cohen, Wael A. Harb, et al.. (2020). Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.. Journal of Clinical Oncology. 38(15_suppl). 8017–8017. 5 indexed citations

Rioux, Nathalie, Amy Kim, Darrell Nix, et al.. (2018). Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers. Cancer Chemotherapy and Pharmacology. 83(1). 91–96. 3 indexed citations

O’Reilly, Eileen M., James Roach, Paul Miller, et al.. (2017). Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. The Oncologist. 22(12). 1429–e139. 36 indexed citations

Nix, Darrell, et al.. (2016). TCT-180 Impact of the novel DPP-IV-inhibitor Dutogliptin in combination with G-CSF on survival rates and cardiac remodelling after acute myocardial infarction. Journal of the American College of Cardiology. 68(18). B74–B74. 4 indexed citations

10.

Berenson, James R., et al.. (2009). A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. Journal of Clinical Oncology. 27(15_suppl). e19508–e19508. 7 indexed citations

11.

Cabell, Christopher H., Susan E. Bates, Richard Piekarz, et al.. (2009). Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.. Blood. 114(22). 3709–3709. 15 indexed citations

12.

Whittaker, Sean, Ellen J. Kim, Miles Prince, et al.. (2009). Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.. Blood. 114(22). 3701–3701. 3 indexed citations

13.

Lu, Chuang, Richard Gallegos, Ping Li, et al.. (2006). INVESTIGATION OF DRUG-DRUG INTERACTION POTENTIAL OF BORTEZOMIB IN VIVO IN FEMALE SPRAGUE-DAWLEY RATS AND IN VITRO IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition. 34(4). 702–708. 28 indexed citations

14.

Daniels, J. Scott, Jason Labutti, Ian Parsons, et al.. (2005). HUMAN METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB: IDENTIFICATION OF CIRCULATING METABOLITES. Drug Metabolism and Disposition. 33(6). 771–777. 117 indexed citations

15.

Jagannath, Sundar, Bart Barlogie, James R. Berenson, et al.. (2005). Bortezomib in recurrent and/or refractory multiple myeloma. Cancer. 103(6). 1195–1200. 169 indexed citations

16.

Papandreou, Christos N., Danai Daliani, Darrell Nix, et al.. (2004). Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology. 22(11). 2108–2121. 372 indexed citations

17.

Dieterich, Doug, Michael A. Poles, E A Lew, et al.. (1997). Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Antimicrobial Agents and Chemotherapy. 41(6). 1226–1230. 7 indexed citations

18.

Conner, Dale P., et al.. (1991). Transcutaneous Chemical Collection of Caffeine in Normal Subjects: Relationship to Area Under the Plasma Concentration-Time Curve and Sweat Production. Journal of Investigative Dermatology. 96(2). 186–190. 13 indexed citations

19.

Cook, Jack, Michael H. Silverman, Darrell Nix, et al.. (1990). Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. Antimicrobial Agents and Chemotherapy. 34(6). 974–979. 5 indexed citations

20.

Nix, Darrell, et al.. (1985). Liquid-chromatographic determination of ciprofloxacin in serum and urine.. Clinical Chemistry. 31(5). 684–686. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact